Medicines Co. Aktie
Finanztrends
Deine Einschätzung
Was spricht für und gegen Medicines Co. in den nächsten Jahren?
Pro
?
M****
?
M************
?
U****************
Kontra
?
L*********** I********** f** d** n******* J****
?
W******* i* V********
?
A****************
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Medicines Co. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | -0,13 % | -2,82 % | -18,49 % | -27,06 % | -20,48 % | -31,91 % | -34,12 % |
| Opko Health Inc. | 2,83 % | -2,25 % | -9,77 % | -37,13 % | -12,40 % | 1,02 % | -75,45 % |
| Amicus Therapeutics Inc. | 0,00 % | 0,00 % | -0,83 % | 36,36 % | 0,00 % | -0,89 % | 25,00 % |
Kommentare
News
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year
On February 17, 2026, Baker Bros. Advisors LP disclosed a buy of 437,000 Praxis Precision Medicines (NASDAQ:PRAX) shares, estimated at $81.38 million based on quarterly average pricing.
According to
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million
On February 17, 2026, Perceptive Advisors disclosed a significant buy of 431,432 shares of Praxis Precision Medicines (NASDAQ:PRAX), with an estimated transaction value of $80.34 million based on
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress
On February 13, 2026, Affinity Asset Advisors disclosed a new position in Praxis Precision Medicines (NASDAQ:PRAX), acquiring 185,000 shares in an estimated $54.53 million trade.
According to a SEC